Mirxes觅瑞上市8个月再获超7亿港元融资，配售价较上市价溢价近40%

Group 1 - The global cancer early screening and precision medicine sector is experiencing significant growth, with a market potential reaching hundreds of billions [3] - Mirxes has successfully completed a new share placement, raising approximately 711 million HKD, which will support its strategic development directions including R&D and global commercialization [2][4] - Major international medical and technology companies are investing heavily in the early screening sector, with Abbott's acquisition of Exact Sciences for 21 billion USD marking the largest deal in the medical device industry for the year [3] Group 2 - Mirxes is the only publicly listed early screening company in Asia, focusing on non-invasive blood miRNA testing for cancer detection, and has received regulatory approval for its molecular gastric cancer screening product [4] - The company has a diverse product pipeline, with ongoing developments in lung, colorectal, and breast cancer screening, and is set to launch its colorectal cancer screening product soon [4] - A strategic partnership with Jingtai Technology aims to integrate AI capabilities into early detection and intervention solutions, enhancing Mirxes' competitive edge in the Asian market [5] Group 3 - The Hong Kong capital market is tightening IPO regulations, which may impact new listings, but Mirxes stands out due to its unique product approvals and strong compliance record [5] - The early screening and precision medicine industry is expected to continue its upward trajectory, driven by technological advancements and increasing market demand [5]